Good morning, everyone, and welcome to Pelthos Therapeutics 2025 Fourth Quarter and Fiscal Year Financial Results Conference Call. Pelthos issued a press release today announcing its financial results ...

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported fourth-quarter and full-year 2025 results on its earnings call, highlighting rapid early demand for its lead product ZELSUVMI, two newly acquired ...

ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for ...

Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

An aggressive pneumonia caused by a common organism is being blamed for killing a 39-year-old Tucson man who died after waiting eight hours in a local emergency room while his wife says she pleaded ...

Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...